NO20063328L - Anvendelse av en fettsyresammensetning som innbefatter minst en av EPA og DHA eller kombinasjoner derav - Google Patents

Anvendelse av en fettsyresammensetning som innbefatter minst en av EPA og DHA eller kombinasjoner derav

Info

Publication number
NO20063328L
NO20063328L NO20063328A NO20063328A NO20063328L NO 20063328 L NO20063328 L NO 20063328L NO 20063328 A NO20063328 A NO 20063328A NO 20063328 A NO20063328 A NO 20063328A NO 20063328 L NO20063328 L NO 20063328L
Authority
NO
Norway
Prior art keywords
fatty acid
acid composition
dha
epa
body weight
Prior art date
Application number
NO20063328A
Other languages
English (en)
Other versions
NO336507B1 (no
Inventor
Morten Bryhn
Jan Kopecky
Original Assignee
Pronova Biocare As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pronova Biocare As filed Critical Pronova Biocare As
Publication of NO20063328L publication Critical patent/NO20063328L/no
Publication of NO336507B1 publication Critical patent/NO336507B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Confectionery (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Denne oppfinnelsen vedrører en fremgangsmåte for behandling og forebygging av fedme, en overvektstilstand eller for å kontrollere kroppsvektsreduksjon, der en effektiv mengde av en fettsyresammensetning som innbefatter minst en av (all-Z-omega-3)-5,8,11,14,17-eikosapentaensyre (EPA), og (all-Z-omega-3)-4,7,10,13,16,19dokosaheksaensyre (DHA) eller kombinasjoner derav, administreres til et menneske eller et dyr. Den foreliggende oppfinnelsen vedrører også anvendelse av fettsyre-sammensetningen nevnt over for fremstilling av et medisinsk produkt for å kontrollere kroppsvektsreduksjon, og for å behandle og forebygge fedme eller en overvektstilstand. Videre vedrører den foreliggende oppfinnelsen også anvendelse av en fettsyresammensetning som innbefatter minst en av EPA og DHA, eller kombinasjoner derav, for fremstilling av et næringsmiddel eller kosttilskudd for å kontrollere og understøtte kroppsvektsreduksjon og for å forebygge kroppsvektsøkning. I tillegg inkluderer den foreliggende oppfinnelsen også et diettprodukt som inneholder en fettsyresammensetning som innbefatter minst en av EPA og DHA eller kombinasjoner derav, for ikke-medisinsk behandling av fedme, en overvektstilstand og/eller for å understøtte og kontrollere kroppsvektsreduksjon. Endelig vedrører den foreliggende oppfinnelsen en fremgangsmåte for å supplere et diettprodukt med en fettsyresammensetning som nevnt over.
NO20063328A 2003-12-19 2006-07-18 Anvendelse av en fettsyresammensetning som innbefatter EPA og DHA NO336507B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53064403P 2003-12-19 2003-12-19
SE0303513A SE0303513D0 (sv) 2003-12-19 2003-12-19 Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof
PCT/IB2004/004178 WO2005060954A1 (en) 2003-12-19 2004-12-17 Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof

Publications (2)

Publication Number Publication Date
NO20063328L true NO20063328L (no) 2006-09-19
NO336507B1 NO336507B1 (no) 2015-09-14

Family

ID=30768831

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063328A NO336507B1 (no) 2003-12-19 2006-07-18 Anvendelse av en fettsyresammensetning som innbefatter EPA og DHA

Country Status (12)

Country Link
US (1) US9282760B2 (no)
EP (2) EP1699449B1 (no)
JP (2) JP2007514733A (no)
CN (2) CN1901897A (no)
AU (1) AU2004305325B2 (no)
CA (1) CA2549103C (no)
ES (1) ES2451030T3 (no)
NO (1) NO336507B1 (no)
NZ (1) NZ547831A (no)
PL (1) PL1699449T3 (no)
SE (1) SE0303513D0 (no)
WO (1) WO2005060954A1 (no)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006017627A2 (en) * 2004-08-06 2006-02-16 Barry Sears Dietary compositions comprising docosahexaenoic acid and eicosapentaenoic acid and use thereof for treating insulin resistance
JP2008540394A (ja) 2005-05-04 2008-11-20 プロノヴァ バイオファーマ ノルゲ アクティーゼルスカブ 脂肪酸組成物、即ち、ｄｈａ誘導体の医薬としての使用
DK1800675T3 (da) * 2005-12-23 2011-09-05 Nutricia Nv Sammensætninger omfattende polyumættede fedtsyrer, proteiner og mangan og/eller molybdæn og nucleosider/nucleotider til behandling af demens
EP1976501B1 (en) * 2005-12-29 2014-10-22 Hill's Pet Nutrition, Inc. Compositions and methods for preventing or treating inflammatory bowel disease
CA2642969A1 (en) * 2006-02-28 2007-09-07 Bristol-Myers Squibb Company Use of dha and ara for increasing lean muscle mass and decreasing adipose tissue in infants
EP1886680A1 (en) * 2006-05-23 2008-02-13 Nestec S.A. Maternal supplement
AU2007282912A1 (en) * 2006-08-09 2008-02-14 The Iams Company Methods of improving bone health and muscle health
BRPI0717972A2 (pt) * 2006-11-01 2013-11-12 Pronova Biopharma Norge As Lipídeos de ômega-3 alfa-substituídos que são ativadores ou moduladores do receptor ativado por proliferadores de peroxissoma (ppar)
RU2009120568A (ru) * 2006-11-01 2010-12-10 Пронова Биофарма Норге Ас (No) Композиция
KR101438177B1 (ko) * 2006-11-01 2014-09-05 프로노바 바이오파마 너지 에이에스 페록시솜 증식자-활성화 수용체의 활성자 또는 조절자인 알파-치환된 오메가-3 지질
CA2667153A1 (en) * 2006-11-03 2008-11-20 Pronova Biopharma Norge As Fatty acid alcohols
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
US20090197955A1 (en) * 2008-01-31 2009-08-06 Monsanto Company Methods of improving dha deposition and related function and/or development
WO2009134147A1 (en) * 2008-05-02 2009-11-05 Pronova Biopharma Norge As Lipid compositions containing derivatives of epa and dha an their use thereof
EP2334295B1 (en) 2008-09-02 2017-06-28 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
WO2010119319A1 (en) * 2009-03-09 2010-10-21 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a free fatty acid, and methods and uses thereof
US8207363B2 (en) 2009-03-19 2012-06-26 Martek Biosciences Corporation Thraustochytrids, fatty acid compositions, and methods of making and uses thereof
NZ624963A (en) 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
SG10201605794PA (en) 2009-04-29 2016-09-29 Amarin Pharmaceuticals Ie Ltd Stable Pharmaceutical Composition And Methods Of Using Same
DK2440065T3 (en) 2009-06-12 2018-12-10 Calanus As COPYPOD OIL COMPOSITION, FORMULATIONS CONTAINING THE OIL COMPOSITION, AND ITS APPLICATION FOR REDUCING VISCAL FAT COLLECTION, IMPROVEMENT OF GLUCOSET TOLERANCE AND PREVENTION OR TREATMENT OF PATIENTS
EP3318255B1 (en) 2009-06-15 2021-03-10 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating stroke in a subject on concomitant statin therapy
AU2010298222B2 (en) 2009-09-23 2017-01-05 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
AU2010309517B2 (en) * 2009-10-23 2016-10-20 Pronova Biopharma Norge As Coated capsules and tablets of a fatty acid oil mixture
US9924733B2 (en) 2010-01-19 2018-03-27 Dsm Ip Assets B.V. Eicosapentaenoic acid-producing microorganisms, fatty acid compositions, and methods of making and uses thereof
JP5576699B2 (ja) * 2010-04-15 2014-08-20 花王株式会社 Ｇｉｐ上昇抑制剤
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ744990A (en) 2010-11-29 2019-10-25 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
JP2014502165A (ja) * 2010-12-20 2014-01-30 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド 満腹応答を誘導するためのペットフード組成物
CN103813789A (zh) * 2011-07-07 2014-05-21 持田制药株式会社 含有高纯度epa的抗肥胖药
AU2012285806B2 (en) 2011-07-21 2017-09-14 Dsm Ip Assets B.V. Fatty acid compositions
JP2013063937A (ja) * 2011-09-20 2013-04-11 Kao Corp Ｇｉｐ上昇抑制剤
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
WO2013070735A1 (en) 2011-11-07 2013-05-16 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
ES2891473T3 (es) 2012-01-06 2022-01-28 Amarin Pharmaceuticals Ie Ltd Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
UA114615C2 (uk) 2012-01-06 2017-07-10 Омтера Фармасьютікалз, Інк. Збагачена дпк композиція омега-3 поліненасичених жирних кислот у формі вільної кислоти
EP3072510B1 (en) 2012-03-30 2019-05-08 Micelle BioPharma, Inc. Omega-3 fatty acid ester compositions
US20160228397A1 (en) 2012-03-30 2016-08-11 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions
US9480651B2 (en) 2012-03-30 2016-11-01 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions unitary pharmaceutical dosage forms
US10898458B2 (en) 2012-03-30 2021-01-26 Micelle Biopharma, Inc. Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states
HK1206248A1 (en) 2012-05-07 2016-01-08 Omthera Pharmaceuticals Inc. Compositions of statins and omega-3 fatty acids
NZ727849A (en) 2012-06-29 2018-06-29 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
FI3626806T3 (fi) 2013-12-20 2024-08-22 Mara Renewables Corp Menetelmiä öljyn talteenottamiseksi mikro-organismeista
EP3906920A1 (en) * 2014-06-06 2021-11-10 Marine Ingredients, LLC Omega-3 compositions, dosage forms, and methods of use
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10851395B2 (en) 2016-06-10 2020-12-01 MARA Renewables Corporation Method of making lipids with improved cold flow properties
CN107970232A (zh) * 2016-10-21 2018-05-01 玛鲁哈日鲁株式会社 含n-3系不饱和脂肪酸的组合物、及n-3系不饱和脂肪酸在该组合物的制造中的应用
EP3559206B1 (en) 2016-12-22 2025-12-03 Mara Renewables Corporation Methods for producing biomass rich in dha, palmitic acid and protein using a eukaryotic microorganism
EP3612570A4 (en) 2017-04-17 2021-01-13 The University of Chicago POLYMERIC MATERIALS FOR THE ADMINISTRATION OF SHORT-CHAIN FATTY ACIDS TO THE INTESTINE FOR HUMAN HEALTH AND DISEASE TREATMENT APPLICATIONS
TW201900160A (zh) 2017-05-19 2019-01-01 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
AU2018354090B2 (en) 2017-10-23 2024-10-24 Epitracker, Inc. Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
AU2019274431B2 (en) 2018-05-23 2025-03-13 Epitracker, Inc. Compositions and methods for diagnosis and treatment of conditions related to the quality of aging and longevity
CN108721269A (zh) * 2018-07-10 2018-11-02 广东海洋大学 一种epa与dha混合剂在防治焦虑和快感缺乏方面的应用
LT3750536T (lt) 2018-09-24 2026-03-25 Amarin Pharmaceuticals Ireland Limited Širdies ir kraujagyslių sistemos reiškinių rizikos subjekto organizme sumažinimo būdai
CN109463512A (zh) * 2018-12-10 2019-03-15 瞿瀚鹏 Dha油脂组合物在凝胶糖果中的应用以及凝胶糖果及其制备方法
CN109646430A (zh) * 2018-12-26 2019-04-19 江南大学 n-3多不饱和脂肪酸在制备预防沙门氏菌感染药物中的应用
EP3908374A4 (en) 2019-01-09 2022-12-28 Epitracker, Inc. COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES
FR3092968B1 (fr) * 2019-02-22 2021-05-21 Microphyt Complement alimentaire
WO2020180814A1 (en) 2019-03-04 2020-09-10 Epitracker, Inc. Fatty acid analogs and their use in the treatment of cognitive impairment, behavioral conditions, and chronic pain
BR112022009189A2 (pt) 2019-11-12 2022-07-26 Amarin Pharmaceuticals Ie Ltd Métodos para reduzir o risco de eventos cardiovasculares em um sujeito com fibrilação atrial e/ou palpitação atrial
EP4099834A4 (en) * 2020-02-06 2024-03-06 DSM IP Assets B.V. Method for increasing eicosapentaenoic acid level in the plasma of an animal
MX2022012322A (es) 2020-04-03 2022-11-10 Mara Renewables Corp Aceites microbianos con niveles altos de ácidos grasos omega-3.
AU2021329343A1 (en) * 2020-08-20 2023-03-09 Epitracker, Inc. Compositions and methods for treatment of obesity
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
EP4426130A1 (en) 2021-11-03 2024-09-11 Epitracker, Inc. Pentadecanoylcarnitine for treatment of conditions related to the quality of aging and longevity

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US565667A (en) * 1896-08-11 Churn
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
JPH0394655A (ja) 1989-09-06 1991-04-19 Otsuka Pharmaceut Co Ltd 栄養補給用組成物
JPH0398560A (ja) 1989-09-09 1991-04-24 Toa Kogyo Kk 餃子と餃子製造機の成形用形枠
US5013569A (en) * 1990-05-21 1991-05-07 Century Laboratories, Inc. Infant formula
JP3092180B2 (ja) 1991-02-27 2000-09-25 日本油脂株式会社 低密度リポ蛋白受容体活性化剤
JP3098560B2 (ja) 1991-03-28 2000-10-16 花王株式会社 体重増加抑制剤
JPH06116585A (ja) 1992-10-09 1994-04-26 Kanegafuchi Chem Ind Co Ltd 油脂の精製方法
TW360501B (en) * 1996-06-27 1999-06-11 Nestle Sa Dietetically balanced milk product
WO1999029316A1 (en) 1997-12-10 1999-06-17 Severson, Mary, L. Pharmaceutical compositions containing an omega-3 fatty acid oil
JP2872986B1 (ja) 1998-01-21 1999-03-24 池田食研株式会社 高純度高度不飽和脂肪酸の低級アルコールエステル精製方法
US6596302B2 (en) * 2000-04-13 2003-07-22 Abbott Laboratories Infant formulas containing long-chain polyunsaturated fatty acids and uses thereof
JP2002188096A (ja) * 2000-10-12 2002-07-05 Kanegafuchi Chem Ind Co Ltd 新規なグリセリドおよびその製造法並びにその用途
JP2002180082A (ja) * 2000-12-11 2002-06-26 Maruha Corp 摂取物
ITMI20010129A1 (it) * 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
JP4337273B2 (ja) 2001-04-20 2009-09-30 日本水産株式会社 基礎代謝増進剤
WO2003005836A2 (en) * 2001-07-10 2003-01-23 Trustees Of Boston University Modified-fat nutritional products useful for preventing or treating obesity
US20030203004A1 (en) * 2002-04-24 2003-10-30 Kelm Gary Robert Compositions comprising short and long chain fatty acids and methods of their use for the management of body weight
TW200412942A (en) 2002-08-06 2004-08-01 Abbott Lab Appetite control method
CN1309813C (zh) * 2002-08-07 2007-04-11 花王株式会社 油脂组合物

Also Published As

Publication number Publication date
ES2451030T3 (es) 2014-03-26
CA2549103C (en) 2013-11-26
AU2004305325B2 (en) 2008-02-07
NO336507B1 (no) 2015-09-14
CN1901897A (zh) 2007-01-24
EP1699449A1 (en) 2006-09-13
CN102861004A (zh) 2013-01-09
CA2549103A1 (en) 2005-07-07
EP1699449B1 (en) 2014-01-22
NZ547831A (en) 2009-11-27
WO2005060954A1 (en) 2005-07-07
AU2004305325A1 (en) 2005-07-07
US20070112071A1 (en) 2007-05-17
SE0303513D0 (sv) 2003-12-19
PL1699449T3 (pl) 2014-06-30
JP2007514733A (ja) 2007-06-07
US9282760B2 (en) 2016-03-15
EP2301530A1 (en) 2011-03-30
JP2012211147A (ja) 2012-11-01

Similar Documents

Publication Publication Date Title
NO20063328L (no) Anvendelse av en fettsyresammensetning som innbefatter minst en av EPA og DHA eller kombinasjoner derav
Tavafzadeh et al. Bone mechanical properties and mineral density in response to cessation of jumping exercise and honey supplementation in young female rats
Hernández et al. 17β-Estradiol prevents oxidative stress and decreases blood pressure in ovariectomized rats
US5597585A (en) Vitamin/mineral composition
Choukroun et al. Two neglected biologic risk factors in bone grafting and implantology: high low-density lipoprotein cholesterol and low serum vitamin D
WO2006017627A3 (en) Dietary compositions comprising docosahexaenoic acid and eicosapentaenoic acid and use thereof for treating insulin resistance
Famularo et al. Probiotic lactobacilli: an innovative tool to correct the malabsorption syndrome of vegetarians?
DE60336934D1 (de) Verwendung von igf-1-serumspiegel-erhöhenden indolessigsäure-derivaten zur herstellung eines arzneimittels zur behandlung von verschiedenen krankheiten
WO2003007888A3 (en) Fat accumulation-modulating compounds
WO2003022288A1 (en) Nutritional compositions for controlling blood glucose level
NO20053077L (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
WO2004001383A3 (en) Safe and effective nutritional supplement formulatins and associated regimens adapted to prevent and/or treat targeted diseases or medical or health conditions, and related methods
WO1999023996A3 (en) Compositions containing red rice fermentation products, frementation processes and monascus strains therefor
WO2003000242A3 (en) Method for the treatment of lymphedema using guaifenesin
TW200740379A (en) Nutrition for obese patients
WO2006016363A3 (en) Mixture of phytosterol ester(s) and 1, 3-diglyceride(s) for use in the treatment of medical conditions
CY1108138T1 (el) Χρησιμοποιηση λουπινοκονγλουτινης δια την θεραπευτικη αγωγη διαβητου τυπου ιι
JPS58501676A (ja) 微量物質としてセレニウムをヒトに供給するための混合物、ならびに細胞培養のための培地中に器官を保存する溶液および血液成分を保存する栄養溶液におけるその使用
DE602005010876D1 (de) Neuartige biaromatische ppar-rezeptoren aktivierende zusammensetzungen und ihre verwendung in kosmetischen oder pharmazeutischen zusammensetzungen
WO2007002836A3 (en) Methods and compositions for the prevention and treatment of kidney disease
TR200100897T2 (tr) Lipid metabolizma bozukluklarının tedavisinde safra asitleriyle bağlı propanolamin türevleri.
KR20170028635A (ko) 지방간을 갖는 골다공증 동물 모델의 생산 방법
WO2007075255B1 (en) Mastic gum composition for use as a dietary supplement in humans and animals
WO2007081486A3 (en) Oral administration of defensins to treat intestinal diseases
Jeddi et al. The potential role of nitrate, a nitric oxide donor, in the prevention and treatment of diabetic osteoporosis

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees